312937-01-2

Basic information

• Product Name: 2,2,2-trifluoro-N-(2-(1-trityl-1H-imidazol-4-yl)ethyl)acetamide
• Synonyms: 2,2,2-trifluoro-N-(2-(1-trityl-1H-imidazol-4-yl)ethyl)acetamide
• CAS NO: 312937-01-2
• Molecular Weight: 449.475
• Mol File: 312937-01-2.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 2,2,2-trifluoro-N-(2-(1-trityl-1H-imidazol-4-yl)ethyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2,2-trifluoro-N-(2-(1-trityl-1H-imidazol-4-yl)ethyl)acetamide(312937-01-2)
• EPA Substance Registry System: 2,2,2-trifluoro-N-(2-(1-trityl-1H-imidazol-4-yl)ethyl)acetamide(312937-01-2)

Safety Data

• Hazardous Substances Data: 312937-01-2(Hazardous Substances Data)

Upstream product

• 56-92-8 histamine dichloride 
• 76-83-5 trityl chloride 
• 383-63-1 ethyl trifluoroacetate, 
• 51-45-6 histamine 
• 50580-77-3 2,2,2-trifluoro-N-[2-(1H-imidazol-4-yl)ethyl]acetamide 

Downstream Products

• 340179-89-7 (1-trityl-1H-imidazol-4-yl)methylamine 
• 476494-04-9 1-[7-((Methanesulfonyl)oxy)naphthyl]-4-[2-(1-triphenylmethyl-4-imidazolyl)-ethyl]-2-piperazinone 
• 476494-03-8 methanesulfonic acid 8-{2-[2-(1-trityl-1H-imidazol-4-yl)-ethylamino]-acetylamino}-naphthalen-2-yl ester 
• 254108-76-4 methanesulfonic acid 8-(4-{2-[3-(4-bromo-3-fluoro-benzyl)-3H-imidazol-4-yl]-ethyl}-2-oxo-piperazin-1-yl)-naphthalen-2-yl ester 
• 312937-07-8 1-(3-chloro-phenyl)-4-[2-(1-trityl-1H-imidazol-4-yl)-ethyl]-piperazin-2-one 
• 312937-03-4 N-(3-chloro-phenyl)-2-[2-(1-trityl-1H-imidazol-4-yl)-ethylamino]-acetamide 
• 620972-31-8 N-[2-(3-benzyl-2-cyclopentyl-3H-imidazol-4-yl)-ethyl]-2,2,2-trifluoro-acetamide 
• 620972-32-9 N-[2-(3-benzyl-2-cyclobutyl-3H-imidazol-4-yl)-ethyl]-2,2,2-trifluoro-acetamide 
• 620972-30-7 N-[2-(3-benzyl-2-tert-butyl-3H-imidazol-4-yl)-ethyl]-2,2,2-trifluoro-acetamide 
• 620972-33-0 N-[2-(3-benzyl-2-cyclopropyl-3H-imidazol-4-yl)-ethyl]-2,2,2-trifluoro-acetamide 
• 620972-22-7 α-N-trifluoroacetyl-3-benzylhistamine 
• 195053-92-0 1-(Triphenylmethyl)-4-(2-amino-1-ethyl)imidazole 

Relevant articles and documents

GLP RECEPTOR AGONISTS

The disclosures herein relate to novel compounds of formula (1 ): and salts thereof, wherein Q, W, X, Y, Z, AA1, AA2, AA3, AA4, AA5, AA6, AA7, AA8, AA9, LysR, R1, R2 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with Glucagon-like peptide (GLP) receptors.

Tyrosinase and catechol oxidase activity of copper(I) complexes supported by imidazole-based ligands: structure–reactivity correlations

Four new imidazole-based ligands, 4-((1H-imidazol-4-yl)methyl)-2-phenyl-4,5-dihydrooxyzole (LOL1), 4-((1H-imidazol-4-yl)methyl)-2-(tert-butyl)-4,5-dihydrooxyzole (LOL2), 4-((1H-imidazol-4-yl)methyl)-2-methyl-4,5-dihydrooxyzole (LOL3), and N-(2,2-dimethylpropylidene)-2-(1-trityl-1H-imidazol-4-yl-)ethyl amine (Limz1), have been synthesized. The corresponding copper(I) complexes [Cu(I)(LOL1)(CH3CN)]PF6 (CuLOL1), [Cu(I)(LOL2)(CH3CN)]PF6 (CuLOL2), [Cu(I)(LOL3)(CH3CN)]PF6 (CuLOL3), [Cu(I)(Limz1)(CH3CN)2]PF6 (CuLimz1) as well as the Cu(I) complex derived from the known ligand bis(1-methylimidazol-2-yl)methane (BIMZ), [Cu(I)(BIMZ)(CH3CN)]PF6 (CuBIMZ), are screened as catalysts for the oxidation of 3,5-di-tert-butylcatechol (3,5-DTBC-H2) to 3,5-di-tert-butylquinone (3,5-DTBQ). The primary reaction product of these oxidations is 3,5-di-tert-butylsemiquinone (3,5-DTBSQ) which slowly converts to 3,5-DTBQ. Saturation kinetic studies reveal a trend of catalytic activity in the order CuLOL3?≈?CuLOL1?>?CuBIMZ?>?CuLOL2?>?CuLimz1. Additionally, the catalytic activity of the copper(I) complexes towards the oxygenation of monophenols is investigated. As substrates 2,4-di-tert-butylphenol (2,4-DTBP-H), 3-tert-butylphenol (3-TBP-H), 4-methoxyphenol (4-MeOP-H), N-acetyl-l-tyrosine ethyl ester monohydrate (NATEE) and 8-hydroxyquinoline are employed. The oxygenation products are identified and characterized with the help of UV/Vis and NMR spectroscopy, mass spectrometry, and fluorescence measurements. Whereas the copper complexes with ligands containing combinations of imidazole and imine functions or two imidazole units (CuLimz1 and CuBIMZ) are found to exhibit catalytic tyrosinase activity, the systems with ligands containing oxazoline just mediate a stoichiometric conversion. Correlations between the structures of the complexes and their reactivities are discussed.

1,3 AND 1,3,5 SUBSTITUTED IMIDAZOLES AS ANTIHYPERTENSIVES

The present invention provides novel 1,5 and 1,3,5-substituted imidazole compounds of formulas (I), (IIa), (IIIb) in hydrophilic or lipophilic form, which are useful as angiotensin II AT1 receptor antagonists with sympathetic suppressant properties. In particular, the invention provides pharmaceutical compositions containing the pharmacophoric groups of Losartan and Clonidine as well compounds, processes and intermediates for preparing compounds and their use in methods of treating hypertension and cardiovascular diseases through Renin Angiotensin System (RAS) and Sympathetic System (SS). Alkylated histamine based double action Saltans are lipophilic and can act transdermally.